This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OBJECTIVE: The goal of this study is to test the hypothesis that MM (2.5 Grams /day) in combination with prednisone (20 mg/d) provides better control of myasthenic signs and symptoms than prednisone alone in the initial management of MG. An open label extension will supply further information about the safety and tolerability of MM at does ranging from 2.5 to 3 grams/day and will give preliminary information about tapering and discontinuing prednisone in patients maintained on MM. RESEARCH PLAN: This is a randomized, double-blind, placebo-controlled, multicenter, trial of MM with moderate-dose prednisone in patients whose MG is not severe. Double blind treatment is three (3) months followed by a 6 month open late phase. Expected multicenter enrollment is 80 patients. METHODS: Subjects will be randomized to receive prednisone 20 mg /day with placebo or with MM 2.5 g/d. Blood work and ADL questionnaire will be administered to assure safety and detect initial improvement. Safety evaluation and assessment of disease severity will occur after 4, 8, and 12 weeks on study medication. Open Label will continue for with safety evaluation and assessments at 13, 14, 15, 16, 20, 28 and 36 weeks. CLINICAL

Public Health Relevance

MG is an uncommon autoimmune disease, affecting about 50,000 patients in the US, in which antibodies to the acetylcholine receptor cause failure of neuromuscular transmission, pathologic fatigue, and weakness. Immunosuppression is used in most MG patients but current treatments are not uniformly effective and carry risk of serious side effects. Preliminary reports have suggested that mycophenolate mofetil (MM), a selective inhibitor of T amp; B-cells used to prevent allograft rejection, is effective and well tolerated in MG. A major advantage of MM, compared to the steroid-sparing agents currently in use, is the rapid onset (within 6 weeks) of its anti-myasthenic action, raising the possibility that initial treatment with MM will lessen the duration/dose of daily corticosteroids and reduce the burden of corticosteroid-related toxicity. This study will furnish key data about the safety and efficacy of MM in MG and represents an important step toward the goal of organ-specific, corticosteroid-free immunosuppressive treatment for this diseas

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR001346-25
Application #
7378172
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2006-04-01
Project End
2007-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
25
Fiscal Year
2006
Total Cost
$12,042
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Kawaguchi-Suzuki, Marina; Cusi, Kenneth; Bril, Fernando et al. (2018) A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. Front Pharmacol 9:752
Hayden, Kathleen M; Baker, Laura D; Bray, George et al. (2018) Long-term impact of intensive lifestyle intervention on cognitive function assessed with the National Institutes of Health Toolbox: The Look AHEAD study. Alzheimers Dement (Amst) 10:41-48
Unick, Jessica L; Gaussoin, Sarah A; Hill, James O et al. (2017) Objectively Assessed Physical Activity and Weight Loss Maintenance among Individuals Enrolled in a Lifestyle Intervention. Obesity (Silver Spring) 25:1903-1909
Kawaguchi-Suzuki, M; Bril, F; Kalavalapalli, S et al. (2017) Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. Aliment Pharmacol Ther 46:56-61
Johnson, Karen C; Bray, George A; Cheskin, Lawrence J et al. (2017) The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial. J Bone Miner Res 32:2278-2287
Lorenzo, Carlos; Festa, Andreas; Hanley, Anthony J et al. (2017) Novel Protein Glycan-Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion. Diabetes Care 40:375-382
Beavers, Kristen M; Leng, Iris; Rapp, Stephen R et al. (2017) Effects of Longitudinal Glucose Exposure on Cognitive and Physical Function: Results from the Action for Health in Diabetes Movement and Memory Study. J Am Geriatr Soc 65:137-145
Chao, Ariana M; Wadden, Thomas A; Gorin, Amy A et al. (2017) Binge Eating and Weight Loss Outcomes in Individuals with Type 2 Diabetes: 4-Year Results from the Look AHEAD Study. Obesity (Silver Spring) 25:1830-1837
Lorenzo, C; Hanley, A J; Rewers, M J et al. (2016) Discriminatory value of alanine aminotransferase for diabetes prediction: the Insulin Resistance Atherosclerosis Study. Diabet Med 33:348-55
Fowler, Sharon P G (2016) Low-calorie sweetener use and energy balance: Results from experimental studies in animals, and large-scale prospective studies in humans. Physiol Behav 164:517-523

Showing the most recent 10 out of 600 publications